Recent Updates
Recently added Catalysts

Progesterone vaginal ring,

Phase 1

Pharmacokinetics | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: Nov 9, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment56
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02092571A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal WomenPHASE1 COMPLETED 56Feb 1, 2014Aug 1, 2014Nov 9, 20211 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
baseline-adjusted AUCt
16 weeks
baseline-adjusted AUC∞
16 weeks
baseline-adjusted Cmax
16 weeks
Secondary Endpoints
baseline-adjusted tmax
16 weeks
baseline-unadjusted AUCt
16 weeks
baseline-adjusted λz
16 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Treatment AEXPERIMENTAL1 ring intravaginal for 7 days, produced from the new process
Treatment BEXPERIMENTAL1 ring intravaginal for 7 days, produced from the legacy process
Interventions
NameTypeDescription
Progesterone vaginal ring,DRUGParticipants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 70 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion: 1. Naturally postmenopausal woman with an intact uterus, 40 to 70 years of age, inclusive. 2. The subject has serum estradiol and FSH levels that are consistent with the subject being postmenopausal. 3. The subject has no clinically significant abnormality findings observed during pelvic...

Countries:United States
Unlock Eligibility Criteria